Exploratory Clinical Trials conference, being held Tuesday 1 and Wednesday 2 December 2009 in Brussels, Belgium, will bring experts from the pharmaceutical and biotech industry together to discuss these issues and the latest developments within the field of exploratory clinical trials. Through a series of presentation, case studies and interactive discussions, participants will gain practical insight into key issues such as gaining regulatory approval, implementing and running exploratory studies successfully and efficiently, the role of biomarkers, utilising effective modelling and simulations tools as well as the mitigation of safety risks.

1. co-loca
the 3rd
ted with ViBpharma
a
Adaptiv nnual
e clinica
Trials co l
nferenc
e
Exploratory clinical Trials
Tuesday 8 and Wednesday 9 December 2009, Sheraton Brussels Airport hotel, Brussels, Belgium
Ensuring faster go/no-go decisions though efficient exploratory
development and studies to maximise cost and time savings
from
ose on of
Cho ecti
l cs to
a se ble topi est
dta lat s
roun uss the ur peer
disc with yo
es
issu
mAiN hiGhLiGhTS iNcLUDE: KEYNOTE SPEAKERS:
Dr. Thomas Senderovitz, Dr. James Dow PhD,
• 16 leading manufacturers Vice President Global Director of Clinical
represented on the programme Exploratory Development, Pharmacology & DMPK,
to deliver case study driven UcB NEW mEDiciNES (OSi) PROSiDiON UK
BELGiUm
presentations Edis Travancic, Director,
Pharmacokinietics &
• Spot on presentation from the Dr. Stephan Formella, Bioanalysis,
MHRA about the new ICH M3 Section head of human BiOViTRUm SWEDEN
guidelines coming into action clinical Pharmacology,
Bruno Boulanger,
BOEhRiNGER
this December 2009 iNGELhEim GERmANY Director Exploratory Studies,
UcB PhARmA BELGiUm
• Benefit from the co-location with
the 3rd annual Adaptive Clinical Prof. Johan Luthman, Gaby Anthonijs,
Vice President, Associate Director
Trials conference to double your Clinical Pharmacology,
Neuroscience R&D,
networking opportunities mERcK USA Exploratory
Development
Department, ASTELLAS
JW mcBlane PhD, PhARmA GLOBAL
Senior Pre-Clinical Assessor, DEVELOPmENT EUROPE
TOP cOmPANiES REPRESENTED iNcLUDE: mhRA UK NEThERLANDS
• UCB • BOEHRINGER INGELHEIM
Erik mannaert, Director
• HOFFMANN LA ROCHE • NOVARTIS Dr. håkan Wennbo, Clinical Pharmacokinetics,
• BAYER • FAMHP Global Project Director, J & J PhARmAcEUTicAL
• MHRA • ASTELLAS Cardiovascular & R&D (a Division of Janssen
Gastrointestinal, Pharmaceutica N.V.)
• ASTRAZENECA • JOHNSON & JOHNSON
ASTRAZENEcA SWEDEN BELGiUm
Sponsors:
Register online now at: www.clinicaltrialsevents.com/exploratory

2. Programme Day One Tuesday 8 December 2009
08:30 Registration ● Linking therapeutic concepts to diseases successfully
● Uncovering a comprehensive evaluation of pharmacodynamic actions
09:00 Opening remarks from the chair to maximise study success
Dr. Thomas Senderovitz, Vice President Global Exploratory ● Identifying the best organisational solutions for integrated R&D
Development, UcB NEW mEDiciNES BELGiUm Prof. Johan Luthman, Vice President, Neuroscience R&D, mERcK USA
Looking into the crystal ball: forecasting the future 12:10 case study:
of the pharmaceutical industry connecting the dots from the pre-clinical phase to
the probability of success: making it a reality through
09:10 Keynote:
the integration of Bayesian statistics
changing the game: a look into the future of Research ● Outlining how to turn information generated in pre-clinical phases
and Development (R&D) in the pharmaceutical industry into direct value
● How can pharma R&D change and become more productive? ● Indicating how modelling is used to improve efficiency of exploratory
● What will the future pharma-healthcare landscape look like? trials through the use of adaptive designs, optimal designs or
● Why is this relevant for you – translational and exploratory Bayesian modelling
medicine experts? ● Introducing prediction-based decision-making and demonstrating the
Dr. Thomas Senderovitz, Vice President Global Exploratory new added value for clinical trials: improving predictions
Development, UcB NEW mEDiciNES BELGiUm ● Using assay performance knowledge to improve clinical trial performance
Giving a broad Bayesian modelling perspective on exploratory
maximising the efficiency of ADmE and PK properties
●
development
to improve the translatability into the clinic Dr. Bruno Boulanger, Director Exploratory Statistics,
UcB PhARmA BELGiUm
09:40 Best practice strategies for the prediction of ADmE
properties in humans from preclinical data 12:40 Effectively overcoming the challenges in Fih studies in
● Using human in vitro data versus animal studies to ensure data accuracy order to maximise study success
● Outlining the role of transporters in human drug disposition to ● Choosing a safe starting dose to ensure compliance with
maximise precision national regulations
● Accurately assessing drug metabolism and the potential role of ● Outlining tools and techniques to maximise the success rate through
metabolites in assessing efficacy and safety the use of practical examples
● Identifying the differences between small molecules and biologics ● Flexible, data driven protocol design to combine SAD and MAD in
Edis Travancic, Director, Pharmacokinietics and Bioanalysis, FIH studies
BiOViTRUm SWEDEN ● Debating if patients in other therapeutic areas to oncology can be
included in FIH studies
10:10 Determining human ADmE/PK early in clinical drug
● Phase 0 microdosing studies – do we really need labelled compounds?
development to forecast and ensure study success Dr. James Dow PhD, Director of clinical Pharmacology and DmPK,
● Running human Phase 0 microdosing studies – debating the (OSi) PROSiDiON UK
pro’s and con’s
● Meeting the US FDA ‘MIST’ guidance using innovative protocol 13:10 Lunch
designs to ensure regulatory compliance
● Determining absolute bioavailability and IV PK without extensive 14:10 Optimising the design of early Phase i studies to
preclinical studies achieve Poc faster
● Is there a new paradigm for determining human PK? ● Selecting appropriate populations to conduct successful early
Prof. colin Garner, molecular Epidemiology, Department of Biology, Phase I studies
UNiVERSiTY OF YORK UK ● Outlining different model based approaches to achieve PoC faster
● Maximising efficiency of PoC and proof-of-mechanism (PoM) studies
10:40 Morning refreshments to improve translatability
Achieving better informed dose selections
Overcoming the challenges of personal medicine
●
michael Derks, metabolic Disease Area clinical Pharmacologist,
and patient selection by utilising selection and hOFFmANN-LA ROchE SWiTZERLAND
diagnostic tools
highlighting the role of animal models in
11:10 case study: translational medicine and how exploratory
Using pre-clinical data to facilitate the development
of patient selection tools
studies benefit
● Maximising the identification of patient populations for personalised 14:40 case study:
healthcare by utilising molecular diagnostics The role of translational medicine in exploratory
● Increasing the likelihood of robust identification of those patients development and its impact on exploratory studies
who would benefit from treatment by using pre-clinical data from ● Exploring the mechanisms of action and potential importance of new
in-vitro systems and samples from undosed volunteers discoveries though effective experimental medicine
● Debating reproducibility, robustness, evaluability, translation and ● Utilising biomarkers to detect drug effects in man and to demonstrate
interpretability as key properties amongst others pharmacological activity and the mechanism of action of novel drugs
● The implications of these inputs for the design of the clinical ● Ensuring a better understanding of the disease mechanism by
programme will be discussed increasing the investment in clinical target validation and by
chris harbron, Technical Lead Statistician, Discovery Statistics, performing more exploratory studies
ASTRAZENEcA UK ● Improving the targeting of new drugs to increase the overall success
rates and the benefits of new drugs for patients
connecting the dots between pre-clinical and first Dr. håkan Wennbo, Global Project Director, cardiovascular and
in human (Fih) studies to maximise the success of Gastrointestinal, ASTRAZENEcA SWEDEN
exploratory studies 15:10 Afternoon refreshments
11:40 Overcoming strategic and technical challenges in bridging
the gap between animal and human pharmacology
● Outlining the need for high translational value of data to support
major transitions

3. Day One Tuesday 8 December 2009 Day Two Wednesday 9 December 2009
Enhancing the identification and validation of 08:30 Registration
biomarkers as a means of reducing costs and 09:00 Opening remarks from the chair
maximising trial outcomes Dr. James Dow PhD, Director of clinical Pharmacology & DmPK,
(OSi) PROSiDiON UK
15:40 Accelerating early clinical development utilising
predictive biomarkers 09:10 Roundtable morning
● Finding the right mechanism of action and Proof-of-Mechanism Delegates will be able to attend three one-hour roundtable discussion
(PoM) of biomarkers to filter out compounds that fail to show groups from a selection of key topics. Each session will be chaired
efficacy in humans by an industry expert who will facilitate an exchange of opinions,
● Speeding the development of biomarkers to the status of essential experiences and learning related to a current aspect of
true surrogates exploratory clinical trials.
● Identifying approved biomarkers as guidance for future approvals
● Case study projects in metabolics Roundtable 1
Dr. Arne Ring, Team Leader Phase i – iia Statistics,
BOEhRiNGER iNGELhEim GERmANY Overcoming the challenge of developing biomarkers
for personalised exploratory clinical trials to improve
16:10 case study: study outcomes
Biomarker development, validation and Discussing critical issues in the development of biomarkers to ensure
implementation from early development to translatability in personalised clinical studies.
clinical studies chris harbron, Technical Lead Statistician, Discovery Statistics,
● Applying PoM, Proof-of-Principle (PoP) and PcC biomarkers in early ASTRAZENEcA UK
development phases to define the correct dosage for healthy subjects,
e.g. FIH and patients Roundtable 2
● Debating biomarkers in early development – values and pitfalls to Exploratory clinical studies as the link between
improve future development pre-clinical and patient studies: how to design Fih,
● The incidence of adverse events in early Phase I – can this be predicted
through the use of biomarkers?
experimental medicine and exploratory studies to
● Outlining the regulatory environment for identifying approval biomarkers gain maximum knowledge
Dr. michael-Friedrich Boettcher, Global clinical Pharmacological Understanding the pros and cons of using patients versus
Project Leader, BAYER SchERiNG PhARmA AG GERmANY healthy volunteers for Phase 0 studies – focusing on scientific,
operational and ethical issues.
Evaluating the potential of exploratory studies Dr. heidemarie Kletzl, clinical Pharmacologist, PDEP clinical
Pharmacology, hOFFmANN-LA ROchE SWiTZERLAND
for biologics
16:40 Opportunities for biologics using exploratory Roundtable 3
clinical trials maximising the exploratory PK and PK/PD
● Identifying optimal trial design for biological exploratory studies investigation in early clinical oncology trials
to achieve go/no-go decisions faster Identifying efficient strategies to measure PK/PD in order to achieve
● Understanding the pros and cons of using patients versus a go/no-go decision faster using oncology trials as an example.
healthy volunteers for Phase 0 studies - scientific, operational Ludy can Beijsterveldt, Director, clinical Pharmacokinetics,
and ethical issues clinical Pharmacology, J & J PhARmAcEUTicAL R&D (a Division
● Optimising safety testing methodologies to assure legislative and of Janssen Pharmaceutica N.V.) BELGiUm
safety compliance
● Debating the potential of using adaptive trial design in early phase Roundtable 4
studies to speed up clinical trials
Dr. Jennifer Sims, Director head NBx Translational Sciences and Translational PK /PD for the design of dosing
Services, NOVARTiS PhARmA AG SWiTZERLAND strategies with monoclonal antibodies
Understanding the role of monoclonal antibodies and how the
17:10 closing remarks from the chair improve the translatability and dosage formulations.
Dr. Stephan Formella, Section head of human clinical Pharmacology,
17:15 close of Day One BOEhRiNGER iNGELhEim GERmANY
Roundtable 5
Predicting human PK - a problem solved?
Debating if animal studies can accurately predict human metabolism
to obtain consensus on the way forward.
Prof. colin Garner, molecular Epidemiology, Department of Biology,
UNiVERSiTY OF YORK UK
Roundtable 6:
Understanding the regulatory environment to
overcome hurdles and challenges
Learning how to overcome regulatory hurdles while setting up
exploratory studies to ensure regulatory compliance
Walter Janssens, PhD, Senior Preclinical Assessor, Preauthorisation,
coordinator Early Phase Development, FEDERAL AGENcY FOR
mEDiciNES AND hEALTh PRODUcTS (FAmhP) BELGiUm
12:30 Lunch
REGISTER ONLINE NOW!
www.clinicaltrialsevents.com/exploratory

4. Sponsors
Day Two Wednesday 9 December 2009 cmed provides CRO services and unique
clinical data technology. Services
include: clinical project management and
Reviewing the ich m3 guidelines and their impact monitoring, data management (eDC/paper) and statistical services.
on exploratory studies Cmed is rapidly gaining a reputation for leadership in the adaptive
13:30 Keynote: The mhRA’s approach to exploratory trial design community through its unrivalled ability to conduct
clinical trials and the ich m3 guidelines: complicated adaptive design studies using patented intelligent data
ensuring faster approvals acquisition/management (iDAM) technology. As Cmed combines
● Defining an exploratory clinical trial and outlining the rising both CRO services and technology within a single organisation it
importance of exploratory studies can execute these studies particularly efficiently without sponsors
● The MHRA’s approach to assessing applications for exploratory to coordinate multiple service providers. www.cmedresearch.com
clinical trials
● ICH M3 and how to maximise your chance of receiving an approval Exhibitors:
for an exploratory clinical trial
● Regulatory perspective of the impact of exploratory clinical trials
on drug development
● Recent experience and future trends for exploratory clinical trials
JW mcBlane PhD, Senior Pre-clinical Assessor, mhRA UK
media partners
The regulatory environment – different angles
Pharmaceutical Technology is
and approaches to ensure regulatory compliance used daily as a means of creating
14:00 Reviewing the regulatory environment for exploratory partnerships and as a point of
studies – FAmhP’s point of view reference by professionals within the pharmaceutical industry.
● Ensuring a balance between regulatory flexibility and stringent This comprehensive resource supplies the latest news releases,
regulations to ensure patient safety detailed information on industry projects, white papers, event
● Maintaining collaborations with the different parties to achieve information and a thorough breakdown of products and services.
global standardisation www.pharmaceutical-technology.com
● A statistical overview of exploratory study approvals in Belgium
● Forecasting future trends of regulatory approval numbers
Drug Development Technology is a
Walter Janssens, PhD, Senior Preclinical Assessor, Preauthorisation,
coordinator Early Phase Development, FEDERAL AGENcY FOR procurement and reference resource
mEDiciNES AND hEALTh PRODUcTS (FAmhP) BELGiUm providing a one-stop-shop for
professionals and decision makers within the drug development
Optimising exploratory studies with an adaptive and medicines industry. We provide a comprehensive breakdown
trial design and operational excellence strategies of drug development contractors and suppliers, up-to-date news
and press releases, white papers and detailed information on
14:30 Adaptive trials in early development current industry projects and trends. Our recruitment area provides
● Why early development is a good setting for adaptive clinical trials
career information and the latest job vacancies in the field.
● Which early development trials are most suited for adaptive clinical trials
● Finding the balance between statistical rigor and practical feasibility www.drugdevelopment-technology.com
● What to worry about when considering a adaptive trial
● Simulation as a indispensable tool to assess performance and The Business Review websites are
feasibility at the design stage your number one stop for all the
Filip De Ridder, Director, Biostatistics & Programming, latest news, comment and industry information. Each Business
JOhNSON & JOhNSON PhARmAcEUTicA R&D Review website offers content that is produced by a dedicated
team of journalists and global industry experts. In addition to the
15:00 Afternoon refreshments
free content made available on the sites an intelligence store will
15:30 Efficiency measures in the conduct of exploratory provide you with premium market analysis reports from the leading
development studies to ensure operational global suppliers of market research and industry analysis.
excellence in exploratory studies
● Focusing on operational excellence to maximise study efficiency Pharmaceutical Business Review is the
● Defining a clear roadmap to success through process world's leading pharma website, being
improvement strategies used by over 100,000 visitors every
● Measuring performance by metric strategies to identify weaknesses month. For further information contact
● Establishing and implementing cross departmental agreements for jsharp@industryreview.com
exploratory development studies
Gaby Anthonijs, Associate Director clinical Pharmacology, Exploratory
World Pharmaceutical Frontiers
Development Department, ASTELLAS PhARmA GLOBAL DEVELOPmENT
The pharmaceutical industry is
World Pharmaceutical Frontiers www.worldpharmaceuticals.net
EUROPE NEThERLANDS
changing fast. There are more
maximising exploraory study success by utilising regulations, technologies, faster product launches and shorter
product life cycles than ever before. World Pharmaceuticals
accurate simulation and forecasting tools
frontiers is, and will continue to be, at the forefront of these
16:00 case examples of physiological-based PK-modeling changes, so visit us at www.worldpharmaceuticals.net and stay
(PBPK) in early clinical development up to date with all latest developments
● Outlining the value of PBPK modeling to reduce uncertainty
Identifying PBPK-based methods as alternative for empirical allometric
●
scaling for the prediction of human PK. if you want to be a part of this
●
●
Improving the prediction of DDI’s (Drug-Drug Interactions)
Examining the prediction of dissolution-limited absorption in human
successful event, we have a number of
Erik mannaert, Director clinical Pharmacokinetics, J & J sponsorship opportunities available.
PhARmAcEUTicAL R&D (a Division of Janssen Pharmaceutica N.V.)
BELGiUm contact Nick mccudden to discuss your specific requirements
nicholasmccudden@arena-international.com or call
16:30 closing remarks and close of conference +4420 7753 4259

5. BOOKiNG FORm
2nd Annual Clinical Trials in Oncology, Tuesday 8 and Wednesday 9 December 2009, Munich, Germany
Prices & Payment information Four Easy Ways To Book:
Yes, i would like to register for the event: BEFORE BEFORE AFTER ■ Register online at
(please tick option) 22.9.2009 20.10.2009 20.10.2009
www.clinicaltrialsevents.com/exploratory
Pharma and Biotech manufacturers
I would like to attend the 2-day conference + €2590 (VAT where €2730 (VAT where €2940 (VAT where ■ Email us at
the interactive CD-ROM (saving €70) applicable) applicable) applicable) events@arena-international.com
€1960 + 21% €2100 + 21% €2310 + 21%
I would like to attend the two day conference only
VAT = €2371.60 VAT = €2541 VAT = €2795.10
■ Tel +44 (0)20 7753 4268
Academic representatives ■ Fax +44 (0)20 7915 9773
I would like the VIP Attendee Package to €1680 (VAT where €1,820 (VAT where €2030 (VAT where
include the 2 day conference and the interactive applicable) applicable) applicable)
CD-ROM (saving €70)
I would like to attend the two day conference only €1050 + VAT €1,190 + VAT €1400 + VAT
@ 21% = €1270.50 @ 21% = €1439.90 @ 21% = €1694
Fees for all other attendees
€3590 €3730 €3940 Venue Details
I would like the VIP Package attendees
(VAT where (VAT where (VAT where The two day conference will take place on Tuesday 8
package to include the two day conference
applicable) applicable) applicable) and Wednesday 9 December 2009. The venue for all
+ interactive CD-ROM
two days will be at the Sheraton Brussels Airport Hotel,
I would like to attend the two day conference €2960 + VAT €3100 + VAT €3310 + VAT Brussels National Airport 1930, Belgium. For further
@ 21% = €3581.60 @ 21% = €3751 @ 21% = €4005.10 information contact our Operations department on
+44 (o) 207 753 4201.
All attendees
Are you registered?
I cannot attend the conference but would like €700 + VAT €700 + VAT €900 + VAT
You will always receive an acknowledgement of your booking.
to receive the interactive CD-ROM If you do not receive anything, please call us on +44 (0) 20
7753 4268 to make sure we have received your booking.
All total fees are subject to a 2.5% service charge
Discount code if applicable _________________________________
Total
Discounts are at the discretion of Arena International and are not cumulative
Arena International Conference Delegate terms and conditions other applicable sales tax which shall be payable in addition. accordance with English law and each party irrevocably agrees that
1. Scope of Agreement: These are the conditions of the contract • Following completion and return of the booking form, full payment the courts of England will have the non-exclusive jurisdiction to deal
between you, the Client (“You” and “your”) and Arena International including Service Charge is required within five days from the invoice with any disputes arising out of or in connection with this agreement.
(“Arena International”, “we”, “us” and “our”) governing your date or prior to the event if this is sooner. All registrants must provide a • Arena International is subject to the UK Data Protection Act 1998
use of our services, including the conference registration as set credit card number as a guarantee at the time of booking. We reserve and is registered in the UK with the Information Commissioner to
out in your booking form. This agreement constitutes the entire the right to charge your card in full process your personal information. Our primary goal in collecting
agreement between Arena International and you. All prior agreements if payment is not received in accordance with these payment terms. personal information from you is to give you an enjoyable customised
understandings and negotiations and representations (save for We reserve the right to refuse admission if full payment is not received experience whilst allowing us to provide services and features that
fraudulent misrepresentation) whether oral or in writing are cancelled in accordance with these terms. most likely meet your needs. We collect certain personal information
in their entirety. The terms of any other electronic communications will 4 Cancellations: In the event of cancellation, 100% of the event fee from you, which you give to us when using our Sites and/or registering
not form part of this agreement. is payable and non-refundable. All cancellation requests must be or subscribing for our products and services. We also collect certain
2 Our commitment to you: Should the Event be cancelled or the submitted to us in writing. If we agree to your cancellation then all personal data from other group companies to whom you have given
location be changed for reasons or circumstances beyond our control, cancellation fees are payable immediately after the acceptance of your information through their websites. The information provided will be
we reserve the right to reschedule the Event, including changing cancellation in writing by us. held on our database and may be shared with other companies within
the location, upon written notice to you. Should the event fail to be the same Group. Occasionally your details may be made available
5 General: You, your executive/s or your agents may not transfer or to our external partners. If you do not want us to continue using this
rescheduled for any reason your refund shall not exceed the total assign any of the rights or obligations of this Agreement (in whole or
charge received by us from you. information please notify us at unsubscribe@spgmedia.com.
part) without our prior consent. Any attempt to resell, assign or transfer
3 Payment Terms: The Total Fees specified on the booking form are rights without our consent will entitle us to cancel the contract without • The working language of the Event is English. Executives
subject to an additional service charge of 2.5% (“Service Charge”) liability to you. requiring an interpretation service must make their own
applied to cover administration costs, and are exclusive of VAT and any • This agreement is governed by and will be construed in arrangements at their own expense.
Delegate Details please photocopy form for multiple bookings
Mr/Mrs/Ms/Dr: First Name: Surname:
Email: Tel: Job Title:
Fax: Department:
company Details
Company: Address:
Town: Postcode: Country:
VAT Number: Nature of Business:
Payment Details
Purchase Order No.
■ I enclose a cheque drawn on a UK bank (please make cheque payable to Arena International and write reference EXCT1209 on the reverse)
■ I will transfer payment to your Lloyds TSB account City Branch, London, UK: 01492549, sort code 30-00-02 (using reference EXCT1209)
■ I would like to pay with my credit card ■ Visa ■ Mastercard ■ AMEX ■ Maestro ■ Solo
Card Number: Expiry Date: Issue Date: CSV*:
Cardholder's Name:
Cardholder's Address:
*The CSV number is the last 3 digit number on the reverse of the card
■ Yes, I have read and understood the terms and cancellations conditions and am happy to proceed with my registration MKEH
Signature Date